TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05697185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
Study: NCT05412446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAPT6-SPECT
Description: Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAPT6-SPECT
Description: Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
Study: NCT06297772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: decitabine 20mg/m2 per day for consecutive 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Injection
Description: fludarabine 30mg/m2 per day for consecutive 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Injection
Description: fludarabine 30mg/m2 per day for consecutive 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan Injection
Description: Busulfan 3.2mg/kg per day for consecutive 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan Injection
Description: Busulfan 3.2mg/kg per day for consecutive 4 days
Study: NCT05867641

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Immersive VR Therapy in Head-Mounted Device (HMD)
Description: Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for three weeks. The caregiver will use the custom VR\&R web-based application on their personal device (laptop, tablet, or mobile phone) to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call).
Study: NCT06443645

Intervention type: DRUG
Intervention: Anthracycline
Description: as standard of care

Intervention type: DRUG
Intervention: Anthracycline
Description: as standard of care
Study: NCT04646434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Undergo EEG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: Undergo EMG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamics (UDS)
Description: Undergo UDS
Study: NCT04313140

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:~* Cinicial MRI (50 minutes)~* Research MRI (Phosphorus Spectroscopy, Sodium Imaging)
Study: NCT04945798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMT
Description: OMT: direct myofascial release for the triplanar diagnonosis to the OA, thoracic outlet, respiratory diaphragm and pelvic diaphragm concluding with a pedal pump for 120 seconds
Study: NCT04448990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS eco 2 Transauricular vagal nerve stimulation
Description: Auricular electrical stimulation will be applied bilaterally using Transcutaneous Electrical Nerve Stimulation device TENS eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany).~tVNS will be applied bilaterally using electrical square impulses delivered in blocks of 9 impulses with a frequency of 100 Hz and a pulse width of 200 μs emitted twice per second resulting in mixed frequency pattern of 100 Hz/2 Hz with the current intensity, that will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS eco 2
Description: Sham
Study: NCT06056752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QH103 Cell Injection
Description: dose escalation (3+3) : dose 1 (3×10\^8CAR+cells) ,dose 2 (1 × 10\^9 CAR+cells）,dose 3 (3 × 10\^9CAR+cells)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine on days-5\~-2,the infusion dose is adjusted according to the subject's condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition
Study: NCT05526027

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CFQ-R questionnaire, SNOT-22 questionnaire, fecal elastase measurement
Description: cf supra
Study: NCT06233695

Intervention type: DRUG
Intervention: Potassium sparing diuretic
Description: Starting Spironolactone or Eplerenone at the time of enrollment.

Intervention type: DRUG
Intervention: Potassium sparing diuretic
Description: Starting Spironolactone or Eplerenone at the time of enrollment.
Study: NCT06444646

Intervention type: OTHER
Intervention: Adipose tissue biopsy
Description: From each patient, two biopsies will be taken during surgery; one from the subcutaneous and one from the visceral adipose tissue.

Intervention type: OTHER
Intervention: Adipose tissue biopsy
Description: From each patient, two biopsies will be taken during surgery; one from the subcutaneous and one from the visceral adipose tissue.

Intervention type: OTHER
Intervention: Blood sampling
Description: From each patient, two venous blood samples (citrate, LiHe and EDTA plasma) will be taken before surgery.

Intervention type: OTHER
Intervention: Blood sampling
Description: From each patient, two venous blood samples (citrate, LiHe and EDTA plasma) will be taken before surgery.

Intervention type: OTHER
Intervention: Questionnaire
Description: Before bariatric surgery, every patient will fill out questions about general health (physical activity, sedentary behavior, sleeping pattern, ...), physical condition before surgery (nausea, food intake, ...), etc.

Intervention type: OTHER
Intervention: Questionnaire
Description: Before bariatric surgery, every patient will fill out questions about general health (physical activity, sedentary behavior, sleeping pattern, ...), physical condition before surgery (nausea, food intake, ...), etc.

Intervention type: OTHER
Intervention: Patient phenotyping
Description: Length and weight will be measured to calculate body mass index (BMI). Waist and hip circumference will be assessed, as well as blood pressure (both systolic and diastolic) and heart rate at rest. Body composition will be determined using a bioelectrical impedance analysis (BIA) in the hospital. Medication use and comorbidities (that are allowed within the in-/exclusion criteria) will also be derived from the patient's medical files with patient's permission.

Intervention type: OTHER
Intervention: Patient phenotyping
Description: Length and weight will be measured to calculate body mass index (BMI). Waist and hip circumference will be assessed, as well as blood pressure (both systolic and diastolic) and heart rate at rest. Body composition will be determined using a bioelectrical impedance analysis (BIA) in the hospital. Medication use and comorbidities (that are allowed within the in-/exclusion criteria) will also be derived from the patient's medical files with patient's permission.
Study: NCT05752214

Intervention type: OTHER
Intervention: WEB Register
Description: Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
Study: NCT05790265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANNE One
Description: Chest sensor for single lead ECG and finger sensor for pulse oximetry.
Study: NCT05902000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Stenting
Description: Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet treatment
Description: Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative Drug Treatment
Description: Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
Study: NCT05070377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 1. structured physical activity sessions by physical education (school), twice a week, with twenty-minute each lesson;~2. self-monitoring plus goal setting by pedometer (out-of-school), progressive goals to achieve weekly;~3. healthy lifestyle guidance ( parents social support).
Study: NCT05481372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Trans-perineal ultrasound and Magnetic resonance image acquisition
Study: NCT05204043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peter Hess® sound massage
Description: The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music relaxation Music Care®
Description: The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: * State Trait Anxiety Inventory (STAI)~* Pain assessment - Visual Analogic Scale (from 0 to 10).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: * State Trait Anxiety Inventory (STAI)~* Pain assessment - Visual Analogic Scale (from 0 to 10).
Study: NCT05919836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic assisted hernia
Description: Percutaneous assisted laparoscopic hernia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hernia by purse string closure
Description: Laparoscopic purse string closure of hernial sac
Study: NCT06251986

Intervention type: OTHER
Intervention: ofatumumab
Description: This is an observational study, there is no treatment allocation.
Study: NCT06358274

Intervention type: OTHER
Intervention: Thru-hiking
Description: planning to embark on the Colorado Trail
Study: NCT05919836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total laparoscopic dissection of hernial sac
Description: Total laparoscopic dissection of hernial sac
Study: NCT06176157

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D2, vitamin D3
Description: comparing parentral D2, D3, to oral D2, D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D2, vitamin D3
Description: comparing parentral D2, D3, to oral D2, D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D2, vitamin D3
Description: comparing parentral D2, D3, to oral D2, D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D2, vitamin D3
Description: comparing parentral D2, D3, to oral D2, D3
Study: NCT04972045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CuminUP60®
Description: 4 capsules, 400 mg / capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CuminUP60®
Description: 4 capsules, 400 mg / capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Description: 4 capsules, 400 mg / capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Description: 4 capsules, 400 mg / capsule
Study: NCT05010460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: orally 100mg every other day for 5-8 days prior to CABG
Study: NCT06472076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05010460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally 100mg every other day for 5-8 days prior to CABG
Study: NCT04825730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Study: NCT05763745

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Ultrasound
Description: Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
Study: NCT05072613

Intervention type: OTHER
Intervention: Malaria screening
Description: Participants are screened for malaria and a dried blood spot is collected from malaria positive cases

Intervention type: OTHER
Intervention: Malaria screening
Description: Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
Study: NCT04848857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
Study: NCT05873166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
Description: Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
Description: Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
Study: NCT05827536

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PKU GOLIKE
Description: PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PKU GOLIKE
Description: PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard of Care
Description: Protein substitute

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard of Care
Description: Protein substitute
Study: NCT05167695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit-based Sleep Health Intervention
Description: A novel low-cost approach derived by leveraging the science of habit formation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit-based Sleep Health Intervention
Description: A novel low-cost approach derived by leveraging the science of habit formation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Description: In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
Study: NCT04827667

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoalveolar lavage
Description: Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoalveolar lavage
Description: Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoalveolar lavage
Description: Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
Study: NCT04587674

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulation
Description: Lead(s) and Implant Pulse Generator
Study: NCT05006014

Intervention type: PROCEDURE
Intervention: Tooth guided immediate implant placement
Description: The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement
Study: NCT05881187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: topical application of riboflavin followed by cross linking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: topical application of riboflavin followed by cross linking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibotice.g vigamox ED Antifungal e.g Dflucan
Description: topical application of antimicropial therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibotice.g vigamox ED Antifungal e.g Dflucan
Description: topical application of antimicropial therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibotice.g vigamox ED Antifungal e.g Dflucan
Description: topical application of antimicropial therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pack cross linking
Description: TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pack cross linking
Description: TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
Study: NCT04788940

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
Study: NCT06025266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of Viscoelastic and mechanical properties with MyotonPRO
Description: MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of Viscoelastic and mechanical properties with MyotonPRO
Description: MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of Viscoelastic and mechanical properties with MyotonPRO
Description: MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.
Study: NCT05506241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynavision D2
Description: Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
Study: NCT05916599

Intervention type: DEVICE
Intervention: ultrasound
Description: a device which is used in intensive care units,
Study: NCT06531434

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, fluorouracil, Radiation
Description: Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.